Can salmeterol be used to relieve an acute asthma attack?

No. The drug has a delayed onset of action (15–30 minutes) and peaks only after 2–4 hours. Rapid-onset short-acting agents (e.g., salbutamol or fenoterol) are used for emergency relief.

What is the advantage of selective β2-adrenergic agonists over non-selective ones?

They selectively target bronchial receptors, providing high bronchodilating efficacy via inhalation while lacking the pronounced cardiac stimulation ($eta_1$-receptors) characteristic of isoprenaline and orciprenaline.

Why are β2-agonists combined with antimuscarinics (anticholinergics)?

This combination provides synergy (mutual enhancement of bronchodilation) and allows a lower dose of the adrenergic agonist, reducing the risk of side effects.

How does salmeterol affect the inflammatory process in the bronchi?

The drug prevents mast cell degranulation, thereby inhibiting the release of inflammatory and allergic mediators in the airways.

Home › Pharmacology › Salmeterol

Salmeterol

Salmeterolum

For medical students2 min readUpdated 2026-10-10

Salmeterol is an inhaled long-acting selective $eta_2$-adrenergic agonist (a drug regulating the peripheral nervous system). Its primary role is to provide sustained and prolonged bronchodilation in chronic obstructive airway diseases.

Drug classSelective β2-adrenergic agonists

Duration of actionUp to 12 hours (long-acting agent)

Route of administrationInhalation

Target siteβ2-adrenergic receptors of bronchi and mast cells

Mechanism of Action and Pharmacodynamics

Like other members of the group (salbutamol, fenoterol, formoterol), salmeterol selectively stimulates $eta_2$-adrenergic receptors. This leads to high bronchodilation efficacy through the relaxation of bronchial smooth muscle.

In addition to direct bronchodilation, the drug possesses important secondary effects:

Mast cell stabilization: prevents their degranulation, thereby inhibiting the release of inflammatory and allergic mediators into the airway lumen.
Improvement of drainage function: facilitates sputum clearance by increasing mucociliary clearance.

Pharmacokinetics: Profile Among Analogs

A key feature of salmeterol lies in its pharmacokinetics following inhalation. Unlike other $eta_2$-adrenergic agonists, it has a delayed onset of action.

Comparative profile:

Short-acting agents (3–6 hours) (e.g., salbutamol, fenoterol): latent period is only 1–3 minutes, peak effect occurs in 30–60 minutes.
Long-acting agents (12 hours):
Formoterol: acts rapidly (onset in 1–3 min), peak in 2 hours.
Salmeterol: latent period of 15–30 minutes, maximum effect develops only after 2–4 hours.

Clinical Application

Due to the slow onset of its effect, salmeterol is strictly unsuitable for relieving acute bronchospasm attacks (short-acting $eta_2$-agonists are the drugs of choice for those scenarios). Its niche is maintenance therapy and prevention.

Combination Therapy in COPD: In clinical practice, it is rational to combine $eta_2$-adrenergic agonists with anticholinergics / muscarinic antagonists (e.g., ipratropium bromide or tiotropium bromide). Goals of this combination:

Achieving synergy (mutual enhancement of the bronchodilating effect).
Reducing the dose of the $eta_2$-agonist, which helps minimize systemic adverse effects.

Prescription Guidelines

The drug is available as a metered-dose inhalation aerosol.

Prescription Example: Rp.: Aerosoli Salmeteroli 0,000025 g D.t.d. N. 1 S. 1 inhalation (25 mcg) twice daily.

Mnemonic

"Salmeterol is the slowest": unlike salbutamol and formoterol, its effect takes 15–30 minutes to appear, making it suitable for prophylaxis rather than emergency rescue.

Frequently asked questions

Can salmeterol be used to relieve an acute asthma attack?: No. The drug has a delayed onset of action (15–30 minutes) and peaks only after 2–4 hours. Rapid-onset short-acting agents (e.g., salbutamol or fenoterol) are used for emergency relief.
What is the advantage of selective β2-adrenergic agonists over non-selective ones?: They selectively target bronchial receptors, providing high bronchodilating efficacy via inhalation while lacking the pronounced cardiac stimulation ($eta_1$-receptors) characteristic of isoprenaline and orciprenaline.
Why are β2-agonists combined with antimuscarinics (anticholinergics)?: This combination provides synergy (mutual enhancement of bronchodilation) and allows a lower dose of the adrenergic agonist, reducing the risk of side effects.
How does salmeterol affect the inflammatory process in the bronchi?: The drug prevents mast cell degranulation, thereby inhibiting the release of inflammatory and allergic mediators in the airways.

Go deeper

Comparative pharmacokinetics of inhaled β2-adrenergic agonists
Mechanism of synergy between β2-adrenergic agonists and muscarinic antagonists
Impact of adrenergic agonists on mucociliary clearance
Differences between salmeterol and formoterol in clinical practice
Non-selective β-adrenergic agonists: reasons for limited use